Nephrology News and Research

RSS

Nephrology is a branch of internal medicine and pediatrics dealing with the study of the function and diseases of the kidney.

NovaBay begins clinical studies for treating impetigo skin infection

NovaBay(R) Pharmaceuticals, Inc. (NYSE-Amex: NBY), (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced today the start of a Phase 2a proof-of-concept study of its lead Aganocide(R) compound NVC-422 in impetigo.

10 Sep 2009

FDA removes clinical hold on HEPLISAV hepatitis B vaccine

Dynavax Technologies Corporation today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the HEPLISAVTM Investigational New Drug (IND) application in individuals with chronic kidney disease.

10 Sep 2009

BioTrends Research Group ranked by Philadelphia 100 for the second consecutive time

For the second year in a row, BioTrends Research Group, Inc. has been ranked as one of the fastest-growing, privately-held companies in the Philadelphia region by the Philadelphia 100, a joint project of the Wharton Small Business Development Center, the Entrepreneurs' Forum of Greater Philadelphia, and the Philadelphia Business Journal.

10 Sep 2009

New form of malarial infection identified

Researchers in Malaysia have identified key laboratory and clinical features of an emerging new form of malaria infection. The research, funded by the Wellcome Trust, confirms the potentially deadly nature of the disease.

10 Sep 2009

Patient enrollment completed in Phase 2b clinical trial for Pyridorin

NephroGenex, Inc., a privately held drug development company focusing on kidney disease, today announced the completion of patient enrollment in its Phase 2b clinical trial (PYR-210) studying the safety and efficacy of its lead drug candidate Pyridorin (pyridoxamine dihydrochloride) in type 2 diabetic patients with overt diabetic nephropathy. Three hundred and seventeen (317) patients have been randomized.

10 Sep 2009

DaVita offers individualized treatment options for students with kidney disease

DaVita Inc. (NYSE: DVA), a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), supports dialysis patients' education by offering individualized treatment options based on optimal patient care standards and social circumstances.

10 Sep 2009

Federal contract awarded to Children's Hospital of Philadelphia to study use of antibiotics in children

In the largest study of its kind, pediatric researchers at The Children's Hospital of Philadelphia have received a federal contract for a project to determine the most beneficial method of using antibiotics to treat urinary tract infections (UTIs) in children.

10 Sep 2009

American International Pathology Laboratories provides jobs to Walter Reed AFIP pathologists

American International Pathology Laboratories (AIPL), a division of Bostwick Laboratories, opens its doors today, providing positions to more than 40 civilian pathologists and staff formerly of the Armed Forces Institute of Pathology at Walter Reed Army Medical Center. The 150-year-old Institute will cease operations when Walter Reed closes under the Federal Base Realignment and Closure program.

9 Sep 2009

New findings may help identify treatments for diabetes and hyperinsulinemia

By investigating a rare and severe form of diabetes in children, University of Iowa researchers have discovered a new molecular mechanism that regulates specialized pancreatic cells and insulin secretion. The mechanism involves a protein called ankyrin, which UI researchers previously linked to potentially fatal human heart arrhythmias.

9 Sep 2009

Nutrisystem D program helps overweight type 2 diabetic people lose weight

Results from a clinical study conducted at the Temple University School of Medicine and published today in the journal Postgraduate Medicine(1), show that a pre-packaged, portion controlled meal plan helped overweight individuals with type 2 diabetes lose significantly more weight and reduce their A1C test scores (a 90-day measure of blood sugar control) by almost a full point greater than those following a standard hospital-based diabetes support and education program, according to the findings.

9 Sep 2009

Regular usage of CGM devices help manage diabetes

The latest data from groundbreaking human clinical trials of the effectiveness of continuous glucose monitors (CGM) show that the primary determinant of improvements in achieving better diabetes control is regular use of monitors - six days per week or more - rather than the age of patients, and that benefits continue well past the time when people with type 1 diabetes begin using the devices - including experiencing fewer low blood sugar emergencies.

9 Sep 2009

Research study examines the depression rate in chronic kidney disease patients

One in five patients with chronic kidney disease is depressed, even before beginning long-term dialysis therapy or developing end-stage renal disease, UT Southwestern Medical Center researchers have found.

9 Sep 2009

Adverse impact of drinking during pregnancy highlighted by health department

In recognition of Fetal Alcohol Spectrum Disorder Awareness Week, the Pennsylvania Department of Health today reminded women about the serious implications of drinking while pregnant.

9 Sep 2009

Axel Ullrich receives the 2009 Dr. Paul Janssen Award for Biomedical Research

Johnson & Johnson today honored the career achievements of Axel Ullrich, Ph.D., with the 2009 Dr. Paul Janssen Award for Biomedical Research. Dr. Ullrich received this award for his scientific discoveries that led to innovative new drugs including Herceptin((R)) (trastuzumab)*, a personalized medicine therapy, which was the first to target a specific type of breast cancer.

8 Sep 2009

Nanotubes destroy kidney tumors

By injecting multiwalled carbon nanotubes (MWCNTs) into tumors and heating them with a quick, 30-second zap of a laser, a multi-institutional team of researchers from the Wake Forest University School of Medicine (WFUSOM), Wake Forest University Center for Nanotechnology and Molecular Materials, Rice University, and Virginia Polytechnic Institute and State University has developed a new type of therapy that effectively kills kidney tumors in nearly 80% of treated mice. Researchers say that the findings, which were published in the Proceedings of the National Academy of Sciences of the United States of America, suggest a potential future cancer treatment for humans.

7 Sep 2009

Five Clinical Research Units established

With the establishment of five new Clinical Research Units the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) hopes to give a further boost to clinical research in Germany and drive progress in the scientific investigation and possibilities for the treatment of disease.

7 Sep 2009

Xcorporeal to trade under the symbol “XCRP” on the Pink Sheets Electronic OTC Market

Xcorporeal, Inc. (Pink Sheets: XCRP) (the “Company” or “Xcorporeal”) announced that, effective as of today, the Company’s common stock commenced trading on the Pink Sheets Electronic OTC Market, an inter-dealer electronic quotation service for securities traded over-the-counter also known as the Pink Sheets, under the symbol “XCRP”.

5 Sep 2009

Texas Senators higlight CMS about the delay in opening many local dialysis facilities

As Congress prepares to reconvene next week following an August recess period filled with wide-ranging local discussion of health care reform, the Texas kidney community expressed hope that the momentum and public desire for health care reform in Washington can help drive momentum and discussion in Texas about the vital need to open 38 end stage renal disease (ESRD) centers still sitting idle, which, if opened, will dramatically expand access to quality dialysis care and create good-paying local jobs.

5 Sep 2009

Winner of 2009 Gerald A. Beathard Fellowship award announced

Lifeline Vascular Access(SM), the nation's leading provider of vascular access management services, today announced that Dr. Stephen Osaguona has been awarded the 2009 Gerald A. Beathard Fellowship in Interventional Nephrology.

5 Sep 2009

Defective chemical bond in biological tissue may be the reason for diseases, say researchers

Researchers at Vanderbilt University Medical Center led by Billy Hudson, Ph.D., have discovered a new chemical bond in biological tissue, a fundamental discovery that helps explain evolutionary adaptation in the animal kingdom and may shed light on human disease.

4 Sep 2009